Market Overview

UPDATE: Aegis Capital Downgrades Galectin Therapeutics

Related GALT
MLV & Co Has Positive Outlook On Galectin Therapeutics Inc
Galectin Issues Statement on Yesterday's Sell Off, Says Attributed To Negative Social Media Posts and Misinterpretation

In a note released Friday morning, Aegis Capital analyst Raghuram Selvaraju downgraded shares of Galectin Therapeutics (NASDAQ: GALT) from Buy to Hold.

The downgrade comes amid result concerns as to whether or not the company will be able to demonstrate clinical effectiveness of its lead drug candidate GR-MD-02. The concerns arose when the second cohort of its Phase 1b trial did not show the same indications of potential anti-fibrotic efficacy as the previous cohort.

Amid the Aegis downgrade, shares of have dropped more than seven percent.

Latest Ratings for GALT

DateFirmActionFromTo
Aug 2014Aegis CapitalDowngradesBuyHold
Apr 2014McNicoll Lewis VlakMaintainsBuy
Feb 2014Aegis CapitalMaintainsBuy

View More Analyst Ratings for GALT
View the Latest Analyst Ratings

Posted-In: Aegis Capital Raghuram SelvarajuAnalyst Color Downgrades Price Target Analyst Ratings Movers

 

Related Articles (GALT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters